Vertex Pharmaceuticals’ (VRTX) “Outperform” Rating Reaffirmed at William Blair
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...
The Globe and Mail20h
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts
The company's collaboration partner, Vertex Pharmaceuticals(NASDAQ: VRTX), made progress activating authorized treatment centers capable of administrating Casgevy, but CRISPR still hasn't reported any ...
Alnylam Pharma (ALNY) Gets a Buy from Bernstein
Bernstein analyst William Pickering maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $310.00.
Bernstein Remains a Buy on BioMarin Pharmaceutical (BMRN)
In a report released today, William Pickering from Bernstein maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with ...
11 Best 3D Printing and Additive Manufacturing Stocks To Buy
D printing is a process where a machine, known as a 3D printer, creates a product or part by layering material over a ...
Why Xometry, Inc. (XMTR) Is Among the Best 3D Printing and Additive Manufacturing Stocks to Buy?
We recently compiled a list of the 11 Best 3D Printing and Additive Manufacturing Stocks To Buy. In this article, we are ...
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.
Vertex Pharmaceuticals: Strategic Advancements and Promising Pipeline Drive Buy Rating
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
Royalty Pharma: Key Strategic Updates To Be Priced In
Read here for highlights on Royalty Pharma's strategic updates, share repurchase program, and dividend increase with ...
Piper Sandler Sticks to Their Buy Rating for Karyopharm Therapeutics (KPTI)
Piper Sandler analyst Christopher Raymond maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) today and set a price ...